Ambio

Ambio is an innovative biotech company developing novel peptide drugs, biosimilar, bioequivalent, and other complex generic drugs, with unmatched expertise and technological advances in synthetic peptide drug development. Ambio has expertise in not only developing complex synthetic peptides to replace recombinant brand peptides but most importantly... understanding of what the FDA's expectation is for the regulatory approval process in such cases. The company is partnering to launch biosimilar drugs targeting blockbuster indications and advancing the company's own pipeline of novel drugs to improve upon existing biologics and peptide drugs in the therapeutic areas of diabetes, obesity, and beyond. The company's mission is to provide high quality and affordable drugs to patients around the world.Read More